Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple Myeloma
Study on Investigational Treatment for a Type of Cancer Affecting Plasma Cells
Attaya Suvannasankha, MD
Primary Investigator
Brief description of study
Detailed description of study
Patients initially presenting to clinic for myeloma will undergo standard clinical assessments including a blood draw and bone marrow aspiration. It will be necessary for
the purposes of the proposed research to conduct a review of the multiple myeloma patients’ medical record to obtain information regarding disease status and survival.
Clinical information is obtained as part of standard of care. To obtain the data, the research team will need to access subjects’ electronic medical records.
In addition, response data will be collected every 90 days +/- 45 days until progression, and progression-free and overall survival will be analyzed using progression and death dates.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple Myeloma, Cancer
-
Age: 18 years - 95 years
-
Gender: All
Inclusion Criteria
4.1.1 Patients undergoing a bone marrow aspiration and blood draw for
initial diagnosis of, or prior to start of salvage therapy for multiple
myeloma. Any stage disease is acceptable.
• Note: Newly diagnosed patients must not have received prior
systemic treatment aside from corticosteroid or local radiation
for pain control or spinal cord compression.
• Note: Patients with a suspicion of multiple myeloma are also
eligible.
4.1.2 Age > 18 years but ≤ 95 years at the time of consent
4.1.3 Must voluntarily sign the most current informed consent and
HIPAA documents prior to study participation.
Exclusion Criteria
4.2.1 Pregnant females
4.2.2 History of bleeding disorders.
4.2.3 subjects who lack consent capacity, as judged by the treating
physician Institutionalized, mentally disabled subjects
4.2.4 Subjects who are prisoners
This study investigates a treatment for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The purpose of the study is to see if the investigational treatment can improve cancer outcomes and bone health.
Participants will have standard clinical assessments, such as blood draws and bone marrow aspirations. The study will review medical records to gather information about the disease and survival. Data will be collected every 90 days to analyze progression and survival.
- Who can participate: Adults aged 18 to 95 years who are diagnosed with multiple myeloma or starting salvage therapy can participate. They must not have had prior systemic treatment except for corticosteroids or local radiation for pain and must sign informed consent.
- Study details: Participants will undergo blood draw and bone marrow aspiration. Medical records will be reviewed to collect clinical information.
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
